First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
Luis G Paz-Ares, Tudor–Eliade Ciuleanu, Manuel Cobo et al. · The Lancet Oncology · 2021
Cited by 1,357 works. doi:10.1016/s1470-2045(20)30641-0
Authors
- Luis G Paz-Ares
- Tudor–Eliade Ciuleanu
- Manuel Cobo
- Michael Schenker
- Bogdan A. Żurawski
- Juliana Janoski De Menezes
- Eduardo Richardet
- Jaafar Bennouna
- Enriqueta Felip
- Óscar Juan
- Aurelia Alexandru
- Hiroshi Sakai
- Alejo Lingua
- Pamela Salman
- Pierre-Jean Souquet
- Pedro De Marchi
- Claudio Marcelo Martin
- Maurice Pérol
- Arnaud Scherpereel
- Shun Lü
References
- SEER Cancer Statistics Review, 1975-2003
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma